Primary source: EMA - What's new RSS
A Type II variation procedure for the extension of indication for selected medicines is now under evaluation by the CHMP from July 24, 2026, to August 20, 2026.
Extending indications for medicines can potentially enhance treatment options available within the EU, impacting patient care and market access for pharmaceutical companies.
Regulatory Intelligence teams must monitor updates regarding the ongoing CHMP evaluation and potential implications for existing marketing authorizations.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Regulatory Intelligence teams must monitor updates regarding the ongoing CHMP evaluation and potential implications for existing marketing authorizations.
The EMA has initiated a Type II variation procedure for an extension of indication that will be evaluated by the CHMP over a specified period. This opens a pathway for marketing authorization for new clinical uses of certain medicines in the EU.
What changed: A Type II variation procedure for the extension of indication for selected medicines is now under evaluation by the CHMP from July 24, 2026, to August 20, 2026.
Why it matters: Extending indications for medicines can potentially enhance treatment options available within the EU, impacting patient care and market access for pharmaceutical companies.
Practical implication: Regulatory Intelligence teams must monitor updates regarding the ongoing CHMP evaluation and potential implications for existing marketing authorizations.
Published from the regulator source ingestion pipeline after PV impact triage.
Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.
Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Marketing authorization holders (MAHs) must review and potentially update their product labeling to align with the new regulations by 11 April 2029 for products authorized before 11 May 2024.
Regulatory Intelligence leads should initiate monitoring of feedback and prepare for potential regulatory adjustments related to the specified substances.
